Lotus Pharmaceutical Co., Ltd. (1795.TW)
- Previous Close
226.00 - Open
228.50 - Bid 230.00 x --
- Ask 230.50 x --
- Day's Range
227.50 - 231.00 - 52 Week Range
172.50 - 323.00 - Volume
1,575,790 - Avg. Volume
1,624,938 - Market Cap (intraday)
60.428B - Beta (5Y Monthly) -0.01
- PE Ratio (TTM)
11.12 - EPS (TTM)
20.72 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield 4.65 (2.06%)
- Ex-Dividend Date Aug 5, 2024
- 1y Target Est
368.00
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products. In addition, it engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. The company has strategic partnership with NRX Pharmaceuticals. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.
www.lotuspharm.com.tw--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 1795.TW
View MorePerformance Overview: 1795.TW
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1795.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1795.TW
View MoreValuation Measures
Market Cap
59.25B
Enterprise Value
66.04B
Trailing P/E
10.90
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.12
Price/Book (mrq)
2.79
Enterprise Value/Revenue
3.45
Enterprise Value/EBITDA
7.61
Financial Highlights
Profitability and Income Statement
Profit Margin
28.59%
Return on Assets (ttm)
11.07%
Return on Equity (ttm)
28.50%
Revenue (ttm)
19.12B
Net Income Avi to Common (ttm)
5.46B
Diluted EPS (ttm)
20.72
Balance Sheet and Cash Flow
Total Cash (mrq)
5.6B
Total Debt/Equity (mrq)
58.93%
Levered Free Cash Flow (ttm)
2.58B